Beyond RHOA, CDC42 and RAC1, RHOB and RHOC emerge as promising candidates in IBD and CRC, based on in vitro data; this supports further research to confirm their role in physiological/pathological conditions in vivo. Here, CDC42 is linked to colorectal carcinoma.